AHL Partners LLP raised its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 5.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 418,079 shares of the medical device company’s stock after purchasing an additional 20,771 shares during the period. AHL Partners LLP owned about 0.58% of Globus Medical worth $13,859,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Globus Medical by 0.8% during the second quarter. BlackRock Inc. now owns 7,448,420 shares of the medical device company’s stock worth $246,914,000 after acquiring an additional 61,138 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Globus Medical by 1.4% during the second quarter. Vanguard Group Inc. now owns 5,712,043 shares of the medical device company’s stock worth $189,355,000 after acquiring an additional 76,345 shares during the last quarter. State Street Corp grew its position in shares of Globus Medical by 3.6% during the first quarter. State Street Corp now owns 2,246,728 shares of the medical device company’s stock worth $66,545,000 after acquiring an additional 77,604 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Globus Medical by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,831,360 shares of the medical device company’s stock worth $54,244,000 after acquiring an additional 44,421 shares during the last quarter. Finally, Oak Ridge Investments LLC grew its position in shares of Globus Medical by 2.3% during the second quarter. Oak Ridge Investments LLC now owns 1,693,195 shares of the medical device company’s stock worth $56,129,000 after acquiring an additional 38,519 shares during the last quarter. Hedge funds and other institutional investors own 65.64% of the company’s stock.

Several equities analysts have recently commented on GMED shares. Gabelli restated a “buy” rating on shares of Globus Medical in a research report on Friday, August 4th. BidaskClub lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 5th. Canaccord Genuity restated a “buy” rating and set a $37.00 price target on shares of Globus Medical in a research report on Friday, August 18th. BTIG Research started coverage on shares of Globus Medical in a research report on Thursday, September 7th. They set a “buy” rating and a $37.00 price target for the company. Finally, Morgan Stanley restated an “equal weight” rating on shares of Globus Medical in a research report on Tuesday, July 11th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $31.38.

ILLEGAL ACTIVITY NOTICE: “AHL Partners LLP Acquires 20,771 Shares of Globus Medical, Inc. (GMED)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/ahl-partners-llp-acquires-20771-shares-of-globus-medical-inc-gmed/1601447.html.

In other news, insider A Brett Murphy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $29.99, for a total value of $449,850.00. Following the completion of the sale, the insider now directly owns 101,217 shares in the company, valued at $3,035,497.83. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 28.21% of the company’s stock.

Shares of Globus Medical, Inc. (NYSE:GMED) traded up 0.75% during trading on Friday, reaching $29.72. 1,062,749 shares of the company were exchanged. Globus Medical, Inc. has a 52-week low of $19.25 and a 52-week high of $34.03. The stock has a market capitalization of $2.86 billion, a P/E ratio of 26.77 and a beta of 0.60. The stock has a 50-day moving average of $29.82 and a 200 day moving average of $30.72.

Globus Medical (NYSE:GMED) last announced its earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The company had revenue of $152.39 million during the quarter, compared to analyst estimates of $150.94 million. During the same period last year, the company posted $0.29 earnings per share. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, equities analysts anticipate that Globus Medical, Inc. will post $1.27 earnings per share for the current fiscal year.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.